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ABSTRACT
Platinum-based chemotherapy is the recommended first-line treatment for high-
grade serous (HGS) epithelial ovarian cancer (EOC). However, most patients relapse 
because of platinum refractory/resistant disease. We aimed at assessing whether 
other drugs, commonly used to treat relapsed HGS-EOC and poorly active in this 
clinical setting, might be more effective against chemotherapy-naïve cancers. We 
collected couples of HGS-EOC samples from the same patients before and after neo-
adjuvant platinum-based chemotherapy. Samples were propagated as Patient Derived 
Xenografts (PDXs) in immunocompromised mice (“xenopatients”). Xenopatients 
were treated in parallel with carboplatin, gemcitabine, pegylated liposomal 
doxorubicin (PLD) and trabectedin. PDXs derived from a naïve HSG-EOC showed 
responsiveness to carboplatin, trabectedin and gemcitabine. The PDXs propagated 
from a tumor mass of the same patient, grown after carboplatin therapy, did no 
longer respond to trabectedin and gemcitabine and showed heterogeneous response 
to carboplatin. In line, the patient experienced clinically platinum-sensitivity first and 
then discordant responses of different tumor sites to platinum re-challenge. Loss 
of PDX responsiveness to drugs was associated with 4-fold increase of NR2F2 gene 
expression. PDXs from another naïve tumor showed complete response to PLD, which 
was lost in the PDXs derived from a mass grown in the same patient after platinum-
based chemotherapy. This patient showed platinum refractoriness and responded 
poorly to PLD as second-line treatment. PDX response to PLD was associated with 
high expression of TOP2A protein. PDXs demonstrated that chemotherapy-naïve HGS-
EOC might display susceptibility to agents not used commonly as first line treatment. 
Data suggest the importance of personalizing also chemotherapy.
INTRODUCTION
The majority of ovarian cancer patients are diagnosed 
with advanced disease for which cytoreductive surgery 
combined with platinum-based chemotherapy is the standard 
treatment [1]. Although the 5-year survival for women with 
advanced cancer has shown improvement, the majority of 
patients still die of the disease. Refractoriness or resistance 
to platinum-based chemotherapy is the main clinical issue. 
Currently, relapsed platinum-sensitive HGS-EOCs are 
successfully platinum re-challenged, while the optimal 
management of refractory/resistant cases is controversial 
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[2]. Targeted agents have been approved for relapsed HGS-
EOC such as Bevacizumab and Olaparib for BRCA1- and 
2-mutated cancers. While these agents improved Progression 
Free Survival (PFS) in comparison with chemotherapy 
alone, no Overall Survival (OS) benefit was shown [3, 
4]. On the other hand, large-scale genomic analyses have 
shown that HGS-EOCs lack recurrent actionable mutations 
[5, 6]. Therefore, it is of great interest to explore further the 
potential of so-called “traditional chemotherapies”.
A range of chemotherapeutic agents other than 
platinum drugs and taxanes has been approved for 
the treatment of ovarian cancer, such as doxorubicin, 
etoposide, topotecan, gemcitabine and trabectedin. These 
are mostly used as second-line drugs, but they resulted 
poorly effective in trials involving large unselected 
populations of relapsed patients. Thus, their choice for 
second-line treatment is usually based on drug’s toxicity 
and patient’s co-morbidity. Moreover, some of these drugs 
have been tested in trials of alternative first or second-
line treatment, in combination with carboplatin or as 
third drug with carboplatin/paclitaxel, in comparison to 
carboplatin and paclitaxel. These alternatives did not result 
consistently superior [see e.g. refs. 7-10].
We and others [11-16] have undertaken the 
development of Patient-Derived Xenografts (PDXs) of 
ovarian cancers, based on the transfer of primary tumors 
directly from the patient into immunocompromised mice. 
PDXs can be propagated in large cohorts of tumor-bearing 
animals (“xenopatients“), which might receive not only 
the treatment devised for patients (co-clinical trial), but 
also simultaneously other drugs. The largest collections 
of ovarian cancers PDXs demonstrated that PDXs reflect 
patient experience [13, 15].
Here, we have used couples of samples derived 
from ovarian cancer patients before and after standard 
chemotherapy to test the efficacy of drugs approved for 
second-line therapy as treatment of naïve cancers.
RESULTS
Establishment in mice (xenopatients) of patient 
derived xenografts (PDXs) of ovarian cancer
PDXs have been established by sampling tumors 
at diagnosis and at cytoreductive surgery performed after 
either 3 or 6 cycles of neo-adjuvant chemotherapy. Thus, 
while patients have been treated according to standard 
international guidelines, cohorts of xenopatients became 
available to receive treatment (Figure 1). For this study, 
cohorts of xenopatients received drugs approved for the 
first- and second-line treatment of EOC.
Two cases of HGS-EOCs are reported here. Both 
patients were administered platinum-based neoadjuvant 
chemotherapy as first-line treatment. Patient 1 was treated 
with 6 cycles of carboplatin. She showed partial response, 
which persisted for more than 6 months, and then was 
platinum re-challenged at relapse. Patient 2 came out to 
be refractory to 3+3 cycles of neoadjuvant chemotherapy 
with carboplatin and taxol and was treated with pegylated 
liposomal doxorubicin (PLD) at relapse; she responded 
partially and transitorily to PLD as second-line treatment.
Two couples of PDX lines were derived from these 
patients, one obtained before chemotherapy and the 
second from mass grown after fist-line chemoterhapy. 
These were: from Patient 1 the PDX lines before (#1BC) 
and post-chemotherapy (#1PC), and from Patient 2 the 
Figure 1: Schematic diagram of the engraftment and propagation of Patient Derived Xenografts (PDXs) and 
preclinical testing of chemotherapeutic drugs. Sample from a patient is collected at either endoscopy, paracentesis or surgery 
and implanted subcutaneously in 1-3 mice. Successfully engrafted xenografts are harvested and re-implanted in a number of mice and 
eventually propagated to obtain cohorts of at minimum six mice for treatment.
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PDX lines before (#2BC) and post-chemotherapy (#2PC). 
These PDX lines were propagated to obtain at least 40 
mice/each (see e.g. Figure 1), to be randomized for the 
subsequent treatment. Original samples and the relevant 
PDXs were classified by the Pathologist as HGS-EOCs 
(Figure 2).
Response of paired PDX lines to first-line and 
second-line chemotherapeutics
Xenopatients carrying each PDX line were 
randomized using the “Analysis Management Module” of 
the Laboratory Assistant Suite [LAS, 17], to obtain five 
comparable cohorts of 5-6 mice.
As shown in Figures 1, 3 and 4, of each PDX line 
five cohorts were treated with either the placebo or one 
of the following chemotherapeutics: carboplatin, used 
commonly as first line therapy, and three drugs approved 
for second line treatment, i.e. gemcitabine, trabectedin 
and pegylated doxorubicin (PLD). Drugs were used 
at doses calculated on the basis of the standardized 
treatments of patients (see Material and Methods 
section).
Notably, both source Patients received carboplatin 
in first line treatment and were either re-challenged with 
carboplatin (the platinum-sensitive Patient 1), or with a 
second line drug, namely PLD (the platinum refractory 
Patient 2), as described in the Methods section.
As shown in Figure 3A the PDX line #1BC obtained 
from the naïve sample of Patient 1 responded not only to 
carboplatin but also to trabectedin and gemcitabine. The 
PDX line #1PC propagated from a sample harvested 
from the same Patient after platinum-based 6-cycle 
chemotherapy no longer responded to trabectedin and 
gemcitabine (Figure 3B). As far as carboplatin, we noticed 
that while the six mice bearing the PDXs #1BC responded 
consistently to carboplatin (Figure 3C), the response 
of the #1PC PDXs reflected high level of intra-tumor 
heterogeneity, being two PDXs out of six either not at all 
or poorly responsive (Figure 3D). This result explained 
the high variability of the median response to carboplatin 
of the post-chemotherapy PDX #1PC line (Figure 3B). 
Going back to the description of the clinical response of 
the Patient 1 to carboplatin re-challenge, it came out that 
some lesions, namely the lymph-node metastases, showed 
significant reduction, while other masses were not reduced 
by carboplatin and caused disease progression.
Figure 4 shows the response of the PDXs propagated 
from the paired samples of Patient 2. In this case, the 
PDXs derived from the naïve sample (#2BC) did not 
respond to all drugs but PLD (Figure 4A) and underwent 
durable shrinkage in all mice (Figure 4C). In line, the 
tumor of the Patient 2, treated with carboplatin and taxol 
was rated as platinum refractory. The response to drugs 
of the #2PC cohorts, obtained from a tumor mass grown 
after first-line platinum based-chemotherapy is shown in 
Figure 2: Histology of the originating tumors and the corresponding PDXs in xenopatients. HS# indicates the serial number 
of the human sample from which the PDXs derive, as reported in the Profiling Protocol list. Bars: 50 μm. Below each human originating 
sample there is the corresponding PDX, indicated again by the serial number in the protocol. For each Patient: on the left, the originating 
sample harvested before the treatment of the patient with neoadjuvant chemotherapy and the relevant PDX; on the right the sample obtained 
after chemotherapy and the relevant PDX.
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Figure 4B. The short-term response to all drugs looked 
superimposable (Figure 4B) to that of the PDXs derived 
from the naïve tumor. However, the response to PLD was 
partial, as the #2PC PDXs underwent volume stabilization 
in the first 30 days, but re-grew in the following days 
(Figure 4D).
The susceptibility of the PDX line #2BC to PLD 
was associated with the over-expression of the TOP2A 
protein (Figure 5), as it has been demonstrated also 
previously [11]. The PDX line derived from the same 
Patient’s sample after chemotherapy (#2PC], which had 
lost susceptibility to PLD was made of cells expressing 
very low level of nuclear TOP2A, comparable to that of 
the PDXs showing resistance to PLD from the beginning, 
such as the PDX lines #1BC and #1PC (Figure 5).
Expression profiling of PDXs obtained before 
and after patient treatment with platinum-based 
chemotherapy
The molecular make-up of PDXs generated from 
tumor samples obtained before and after platinum-based 
chemotherapy has been analyzed using expression 
profiling.
For each PDX line 2-6 xenografts of the P1-
P3 passages were sampled for mRNA extraction, 
cRNA generation and hybridization to microarray. The 
dendrogram (Figure 6A) generated using the unsupervised 
clustering of the 11,866 probes showed that expression 
profiles distinguished the PDX lines generated from the 
two patients, who differed as far as platinum sensitivity. 
Moreover, the dendrogram shows also the separation 
between PDXs derived from the same patient’s samples 
before and after chemotherapy (Figure 6A).
The separation of platinum-sensitive and platinum 
resistant PDXs was confirmed using a dataset recently 
published by Patch et al. [6]. The latter Authors have 
reported the whole-genome DNA and RNA sequencing 
data of HGS-EOC from 92 patients, who received 
platinum-based chemotherapy as part of primary 
treatment, and were classified as either refractory or 
resistant or sensitive to primary treatment. These Authors 
have defined an RNAseq transcription signature of 
sensitive versus resistant tumors made of 129 genes. We 
Figure 3: Treatment of the PDXs derived from Patient 1 with chemotherapeutic drugs. The PDX line #1BC A, C. was obtained 
from the Patient 1’s sample before her treatment with platinum-based chemotherapy. The PDX line #1PC B, D. was obtained from a sample of 
the same Patient 1 at surgery performed after 6 cycles of platinum-based chemotherapy, to which the patient responded with a reduction of tumor 
burden. Panels A and B show the treatment of each cohort of 6 xenopatients as indicated (see also Figure 1). Panels C and D show the response to 
carboplatin of each PDX (numbered according to randomizing software) of the PDX cohorts obtained before (#1BC) and after (#1PC) platinum-
based chemotherapy. Day 0 represent the beginning of mice treatment. Treatment details are reported in the Materials and Methods section.
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have used 73/129 genes, whose probes are present in our 
dataset, to cluster all our PDX samples (Figure 6B). These 
73 genes allowed the separation of the platinum-sensitive 
versus resistant PDXs from the two patients and also of 
the subset of PDXs obtained from the same patients before 
and after chemotherapy. Moreover, 19 out of the 30 top 
ranked set of genes that mainly described the differences 
between the two patients in our dataset were characterized 
by expression variation, which replicated that of the 129 
differentially expressed genes in the published data [6].
Figure 4: Treatment of the PDXs derived from Patient 2 with chemotherapeutic drugs. The PDX line #2BC A, C. was 
obtained from the Patient 2’s sample before her treatment with platinum-based chemotherapy. The PDX line #2PC B, D. was obtained from 
a sample of the same Patient 2 at surgery performed after 3 cycles of platinum-based chemotherapy. Panels A and B show the treatment of 
each cohort of 6 mice as indicated. Panels C and D show the response to the prolonged treatment with PLD of the PDX cohorts derived 
from the two samples, before (#2BC) and after (#2PC) chemotherapy. Day 0 represent the beginning of mice treatment. Treatment details 
are reported in the Materials and Methods section.
Figure 5: Expression of TOP2A protein in the PDXs. A. Representative images showing the immunohistochemical detection of 
TOP2A protein in the indicated PDX line. Bars: 50 μm. B. Percentage of cells showing detectable staining with TOP2A antibody, measured 
using the NIH ImageJ software. The TOP2A signal was estimated by the ratio between the area occupied by positive cells and the total area 
occupied by cancer cells in the same field. Statistical significance was determined using ANOVA test. **P < 0.01.
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Figure 6: Global expression profiling of PDXs propagated from the two Patients’ samples harvested before and after 
chemotherapy. A. Unsupervised hierarchical clustering shown as dendrogram (clustering tree) derived from expression levels of 11,866 
gene probes in the individual PDXs obtained from Patient 1’s (#1BC and #1PC) and Patient 2’s (#2BC and #2PC) samples. Individual 
PDXs were numbered by the randomizing software. The vertical axis on the right shows the level of similarities between PDXs. B. Heat 
map showing the unsupervised hierarchical clustering of the PDXs by means of 73 genes, selected among the 129 genes which defined the 
profiles of platinum-sensitive versus the platinum resistant HGS-EOCs analyzed by Patch et al. [6].
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Among the top differentially expressed genes that 
separated our platinum-sensitive PDX lines (#1BC and 
#1PC) from the resistant ones (#2BC and#2PC), we 
identified IRF-1 (Interferon Regulatory Factor 1) as the 
most reliable marker of platinum sensitivity. Interestingly, 
we have identified IRF-1 previously as a gene associated 
with the response of ovarian cancer cells to platinum 
[18]. Moreover, IRF-1 was also present in the list of 94 
genes, which separated sensitive from refractory/resistant 
HGS-EOCs in the above-mentioned whole genome-wide 
expression analysis [6].
The comparison of the platinum refractory PDXs 
lines obtained from Patient 2 before (#2BC) and after 
chemotherapy (#2PC) demonstrated that the two lines 
were only modestly distinguishable in global expression 
profiling. This is shown not only by the dendrogram of 
Figure 6A but also by the short list of the differentially 
expressed genes (15 genes, see Supplementary Figure S1).
Conversely, the comparison between the #1BC and 
#1PC PDX lines from Patient 1 showed the differential 
expression of 54 genes (Supplementary Figure S1), being 
the NR2F2 gene the most up-regulated (>4-fold). The 54 
genes were also submitted to the Ingenuity Knowledge 
Base to link genes to known functional pathways, and 
to identify gene-to-gene interaction networks. Forty-
nine genes out of 54 were mapped with the Ingenuity 
Pathway knowledge base. The summary of the over-
represented Ingenuity Pathway Analysis (IPA) Diseases 
and Biological Functions is reported in the Supplementary 
Figure S2. Data showed that not only proliferation related 
genes but also motility and migration related genes were 
over-represented and linked to drug resistance. This came 
out to be particularly interesting as it has been recently 
demonstrated that cell motility/migration might be the key 
to tumor growth and drug resistance [19].
DISCUSSION
Data reported here show that PDXs allowed to 
disclose the susceptibility of chemo-naïve ovarian cancer 
to drugs, namely trabectedin, gemcitabine and pegylated 
doxorubicin that are definitely less commonly used as 
first line therapy than in successive lines of treatment. 
Most importantly, the samples harvested and propagated 
as PDXs from the same patient after standard platinum-
based chemotherapy, were no longer susceptible to the 
above drugs.
The use of PLD in primary and relapsed EOC has 
been tested in Phase III trials [7, 8, 20]. Its addition in 
first-line or second-line treatment did not improve overall 
survival (OS). Similarly, OS was not improved by the 
addition of gemcitabine to carboplatin and paclitaxel in 
first line treatment [10]. Trabectedin was never tested in 
naïve ovarian cancer patients but only in second- or third-
line of treatment. All the above studies have been carried 
out in large unselected patients’ populations while data 
shown here suggest that more accurate selection is worth 
being explored to identify possible alternatives as first-line 
treatment.
The expression profiling of the coupled PDX lines 
from the two cases shows once more the high level of inter-
tumor heterogeneity of HGS-EOC, which current histological 
classification does not show and has been comprehensively 
demonstrated by whole genome studies [5, 6].
Conversely, the signatures of platinum resistant 
EOCs identified by the most recent, comprehensive, 
genome-wide expression analysis of HGS-EOC [6] were 
able to separate even the small number of PDX samples 
of our study. Among the genes included in one of these 
signatures, IRF-1 was found as the most differentially 
expressed in our platinum-sensitive versus platinum 
resistant PDXs. The Interferon Regulatory Factors (IRFs) 
are transcription factors involved in immune responses 
and oncogenesis and most of them are classified as tumor 
suppressors. The expression and activation of IRF(s) are 
stimulated by several cytokines and by DNA damage. 
We have already shown also that IRF-1 expression is 
functionally correlated to platinum resistance of ovarian 
cancer cells as it is 2-fold increased after cisplatin 
treatment and limits cell response to this drug [18].
The heterogeneous response of individual PDXs 
of one cohort to carboplatin reproduces the intra-tumor 
heterogeneity (ITH) of ovarian cancer, which has been 
shown already by genetic studies [see e.g. refs. 21-23]. 
The ITH of this PDX line reflected the heterogeneous 
response of the relapsed tumor of the same patient to re-
challenge with carboplatin.
While the concept of patients’ selection and 
personalized treatment is universally accepted when 
targeted therapies are trialed, the possibility of selecting 
patients for chemotherapy is largely neglected. It is 
noteworthy that in most instances biomarkers predict 
resistance rather than susceptibility to chemotherapeutic 
drugs. In EOC too, a range of molecular changes 
have been associated with acquired chemoresistance 
rather to responsiveness [6]. Biomarkers of response to 
chemotherapeutics are more difficult to identify, also 
because most of the drugs inhibit DNA replication. 
However, some of the conventional chemotherapeutics 
have known molecular targets. These are for example 
anthracyclines that inhibit topoisomerases. In line, we 
have recently shown that topoisomerase II gene copy 
gain predicts response of platinum refractory/resistant 
EOC cancers to PLD [11], as well as being associated 
with the response to PLD in breast cancer [24, 25]. We 
show here that the PDXs propagated from a naïve tumor 
showed responsiveness to PLD that was lost in the 
post-chemotherapy sample of the same patient. As the 
former displayed TOP2A high expression and the latter 
did no longer express similar levels of TOP2A, our data 
corroborate the suitability of TOP2A as biomarker of 
response to PLD, which we previously proposed [11].
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NR2F2 was found overexpressed in the PDX 
lines from a post-chemotherapy sample, which was first 
susceptible and then became resistant to gemcitabine and 
trabectedin. This gene has been already linked to ovarian 
cancer onset and progression, as it was found amplified 
in 7% of the 311 HGS-EOC reported in TCGA [5] and 
in 20% of 80 primary HGS-EOC studied by Patch and 
co-workers [6]. This gene has been previously found 
up-regulated in platinum resistant ovarian cancer cells 
[26] and has been strongly associated to poor prognosis 
pancreatic cancer [27], which is usually treated with 
gemcitabine.
Our data confirm the value of PDXs as preclinical 
models and allowed to reveal the potential and unexpected 
susceptibility of naïve cancers to PLD, gemcitabine and 
trabectedin. Conversely, there are substantial limitations 
to the use of the PDX model for current clinical decision 
making [summarized in 28], although pilot studies have 
reported clinical good responses to PDX-guided choice of 
chemotherapeutics [29, 30]. However, the clinical impact 
of these models on precision medicine may be substantial 
through the elucidation of biomarkers of sensitivity or 
resistance with the aim of identifying strategies for future 
patients.
In summary, oncologists have achieved little 
progress in tailoring chemotherapy for cancer. In ovarian 
cancer, cytoreductive surgery associated with platinum-
based chemotherapy remains the standard of care for both 
patients with limited and advanced disease. However, 
since in the long term about 70% of EOC manifests 
refractoriness/resistance to platinum, data showing that 
each tumor might display selective susceptibility to other 
chemotherapeutic drugs indicate that also conventional 
chemotherapy could be more effectively tailored.
MATERIALS AND METHODS
Patients’ characteristics
We have collected paired tumor samples (naïve 
and post-chemotherapy) from EOC patients treated at the 
Candiolo Cancer Institute FPO-IRCCS and in the S. Anna 
Hospital of the Città della Scienza e della Salute di Torino. 
Samples were implanted, propagated and characterized 
according to the “Profiling” Protocol approved by the 
local Ethical Committee. The in depth study of two cases 
is reported here.
Patient 1 of this study was 75 years old and 
underwent ileostomy following bowel obstruction 
for suspected tumor of the left ovary. During surgical 
operation, peritoneal washing and multiple omental and 
peritoneal biopsies were performed; at definitive histology 
HGS-EOC was diagnosed. From an omental node we 
obtained the PDX line #1BC (Before Chemotherapy), 
corresponding to the PDX line #475 of the Protocol. Since 
the patient was not eligible for debulking surgery due to 
the presence of diffused peritoneal carcinomatosis (clinical 
stage FIGO IIIC) and she had significant comorbidity, 
she was treated with neoadjuvant chemotherapy regimen 
consisting of carboplatin alone. Following three cycles 
of chemotherapy, the computed tomography (CT) scan 
compared with baseline CT, revealed shrinkage of the 
ovarian lesion and stability of peritoneal carcinomatosis. 
Moreover, reduction of the serum marker CA125 was 
observed. Additional three cycles were administered. We 
observed disease stability and further reduction of CA125, 
which was 109 U/ml before chemotherapy, 10 U/ml after 
three cycles and 4 U/ml at the end of the treatment. After 
these 6 platinum-based cycles, the patient underwent non 
optimal cytoreductive surgery (residual tumor or R>1 cm). 
The PDX line #1PC (Post Chemotherapy), corresponding 
to the PDX line #1864 of the protocol, was obtained from 
the left ovary removed during this surgery. After 6 months, 
disease progression (in the liver, abdominal lymph nodes 
and pelvis) was observed at CT scan; a subsequent second 
line platinum-based chemotherapy was performed with 
liver and pelvic progression and shrinkage of pelvic and 
lomboaortic lymph nodes after 6 cycles. The patient died 
4 months after the conclusion of chemotherapy.
From the ascites sample of the naïve Patient 2 we 
obtained the PDX line #2BC (Before Chemotherapy), 
corresponding to the PDX line #1898 of the Protocol. 
This patient was a 62 years old woman, who presented at 
the Emergency Room with abdominal pain and dyspeptic 
symptoms; the abdomen CT scan showed the presence 
of a pelvic mass along with diffused omental and 
peritoneal carcinomatosis. At laparoscopy an omental 
biopsy of the mass showed the presence of HGS-EOC 
(clinical stage FIGO IIIC). CA125 was 1,256 U/mL at 
diagnosis. As the tumor was not susceptible of primary 
optimal cytoreduction because of diffused peritoneal 
carcinomatosis, the patient was treated with neoadjuvant 
chemotherapy regimen consisting of carboplatin and 
paclitaxel. Following three cycles of chemotherapy, 
the CT scan revealed partial response of peritoneal 
carcinomatosis. CA125 decreased to 275 U/mL. Thus, 
the patient underwent Interval Debulkyng Surgery (IDS). 
Uterus, ovaries, multiple peritoneal biopsies, pelvic and 
lomboaortic lymph nodes were removed. However, 
cytoreductive surgery was suboptimal (R> 1 cm). From 
an omental node the #2PC (Post Chemotherapy) PDX 
line, corresponding to the PDX#1980 of the Protocol, 
was obtained. Three additional cycles with carboplatin 
and paclitaxel were performed. Three months after 
postoperative chemotherapy, CT scan showed peritoneal 
progression. CA125 was increased to 567 U/mL. Second 
line treatment with pegylated liposomal doxorubicin 
(PLD) was started and after 2 cycles significant reduction 
of CA125 was observed (217 U/mL); moreover, CT scan 
showed disease stability in the peritoneum with only 
modest increase of ascites. Chemotherapy with PLD was 
withdrawn for G2 skin and G3 gastrointestinal toxicity 
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after only 3 cycles. Third line treatment with gemcitabine 
was endeavored, but after 2 cycles the patient displayed 
peritoneal progression and eventually died 5 months 
later.
Patient derived xenografts
Samples (naïve and post-chemotherapy) were 
obtained from patients such as those described above and 
implanted subcutaneously in the right flank of severely 
immunocompromised NOD/Shi-scid/IL-2R γnull mice. 
In our series the take rate was 47%.
Samples from surgery, such as those that gave rise 
to the PDX lines #1BC, #1PC and #2PC, were examined 
and selected by the pathologist free of necrotic tissue. 
We implanted subcutaneously in mice tumor samples 
of 125 mm3, plunged in Matrigel® (BD Biosciences) 
containing medium. The ascites that gave rise to the 
PDX line #2BC was washed, pelleted and examined by 
the pathologist. An aliquot of pellet containing about 
7*106 tumor cells was injected subcutaneously as above. 
As shown in Figure 1, xenografts were propagated in 
two generations of mice and, for each PDX line, cohorts 
of six mice were randomized using the “Analysis 
Management Module” of the Laboratory Assistant 
Suite [LAS, 17], from approximately 40 mice per line 
with established tumors (average volume 200 mm3). 
Cohorts were treated with the following regimens: PLD 
(Lipodox, Sun Pharmaceutical Industries Cranbury, 
NJ 08512) 3 mg/kg, prepared in 5% glucose solution, 
administered once through the tail vein; carboplatin 
(Teva Pharmaceuticals, USA) 25 mg/kg once-
weekly for 4 weeks administered via intraperitoneal 
injection; gemcitabine (Teva Pharmaceuticals, USA) 
100 mg/kg twice-weekly for 4 weeks administered 
via intraperitoneal injection; trabectedin (Yondelis®, 
Pharma Mar, Spain) 200 μg/kg once administered 
through the tail vein.
Tumor size was evaluated twice-weekly with digital 
caliper and volume was calculated using the formula 
4/3π*(d/2)2*D/2, where d is the minor tumor axis and 
D is the major tumor axis. All animal procedures were 
approved by the Ethics Committee of the Candiolo Cancer 
Institute and by the Italian Ministry of Health.
The following samples have been stored from 
PDXs: frozen samples (in Fetal Bovine Serum, plus 
10% DMSO, Sigma Aldrich, USA) in liquid nitrogen 
for subsequent propagation, RNAlater® (Thermo Fisher 
Scientific, USA) embedded samples for molecular 
analyses and formalin-fixed, paraffin embedded (FFPE) 
samples for morphological analyses.
Gene expression analysis
Total cellular RNA was isolated from samples 
stored in RNAlater, using the SV Total RNA Isolation 
kit (Promega, Fitchburg, WI, USA). The RNAs 
were then quantified and inspected by bioanalyzer 
analysis (Agilent Technologies, Waldbrom, Germany). 
Complementary RNAs were generated and hybridized 
according to the Illumina Total Prep RNA Amplification 
Protocol (Illumina, San Diego, CA, USA). Data were 
obtained using the HumanHT-12 version 4 Illumina 
bead array technology. The transcript average 
intensities were calculated using Illumina BeadStudio 
software, and were normalized by the Rank-Invariant 
Method. Normalized data were log2 transformed and 
centered to the median. Principal component analysis 
and hierarchical clustering (ST, Euclidean distance, 
average clustering, 5000 jackknife resampling steps) 
were performed using the Multi Experiment Viewer 
4.9.0 application [31]. Differentially expressed genes 
were identified using the SAM methods implemented in 
the above program. Ingenuity Pathway Analysis (www.
ingenuity.com) was performed for the interpretation of 
the biological significance of the observed differentially 
expressed genes.
Immunohistochemistry
Immunohistochemical studies were performed 
as described [32] to detect topoisomerase II alpha 
(TOP2A) using monoclonal rabbit antibody (D10G9, 
Cell Signalling Technology), in paraffin-embedded 
tumor material. Ten images of each sample were then 
acquired by optical microscope (20x) connected with 
CCD camera. The images were analyzed using the NIH 
ImageJ (W. Rasband, NIH) software. The TOP2A signal 
was estimated by the ratio between the area occupied by 
positive cells and the total area occupied by cancer cells 
in the same field [33].
Statistical analysis
Statistical analysis of the data was performed using 
ANOVA (Microsoft Excel; Microsoft, Redmond, WA, 
USA).
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